Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 7/20 | 0.76 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.55 |
| ▸ | CYP24A1 | Q07973 | 6/20 | 0.54 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.54 |
| ▸ | CYP27A1 | Q02318 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6822323 | 0.91 | CYP19A1 (0.76) | CYP19A1PDE4DCYP24A1CYP26A1CYP27A1 | |
| SCHEMBL7249809 | 0.87 | CYP19A1 (0.80) | CYP19A1CYP24A1CYP26A1CYP27A1 | |
| SCHEMBL6825978 | 0.86 | CYP19A1 (1.00) | CYP19A1PDE4DCYP24A1CYP26A1CYP27A1 | |
| SCHEMBL450331 | 0.83 | CYP19A1 (0.57) | CYP19A1PDE4DCYP26A1 | |
| SCHEMBL6825354 | 0.81 | CYP19A1 (0.73) | CYP19A1 | |
| SCHEMBL8462441 | 0.79 | CYP19A1 (0.65) | CYP19A1PDE4D | |
| SCHEMBL8465629 | 0.79 | LTB4R (0.53) | CYP19A1 | |
| SCHEMBL6827752 | 0.79 | CYP19A1 (0.77) | CYP19A1PDE4D | |
| SCHEMBL9586682 | 0.79 | CYP19A1 (0.48) | CYP19A1PDE4DCYP24A1CYP26A1 | |
| SCHEMBL8465989 | 0.78 | CYP3A4 (0.64) | CYP19A1PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1028110-B1 | NOVEL DIHYDRONAPHTHALENE COMPOUNDS AND PROCESS FOR PRODUCING THE SAME | DAIICHI SEIYAKU CO (JP) | 2004-04-14 | — | — | EP | disclosed |
| US-6559157-B2 | Excellent 17 alpha - hydroxylase/C17-20-lyase and aromatase inhibiting activity, thromboxan A2 synthesis inhibiting activity, useful as preventive and/or therapeutic agents for various male and female sex hormone dependent diseases | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-05-06 | — | — | US | disclosed |
| US-20020032211-A1 | Novel dihydronaphthalene compounds and processes of producing the same | DAIICHI PHARMACEUTICALS CO., LTD. (JP) | 2002-03-14 | — | — | US | disclosed |
| EP-1028110-A1 | NOVEL DIHYDRONAPHTHALENE COMPOUNDS AND PROCESS FOR PRODUCING THE SAME | Yukijirushi Nyugyo Kabushiki Kaisha (JP) | 2000-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032211-A1 | Novel dihydronaphthalene compounds and processes of producing the same | CYP19A1, HSD17B11, CYP17A1 | CYP19A1 1/4885PDE4D 1761/4885CYP24A1 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.